Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy
Copenhagen, Denmark, 21 October 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
End September 2024, Brain+ A/S (“Brain+” or “the Company”) launched its first product, Ayla – your CST Assistant, into the UK dementia care market to support Cognitive Stimulation Therapy (CST). This marked the starting point for the Company to deliver on its ambition to build the first ever scalable dementia care platform and help people affected by dementia live better lives. Subsequently, a new corporate brand and website (www.brain-plus.com) has been published to support UK market outreach and customer awareness. In addition, a series of educative clinical and commercial Brain+ hosted webinars has been kicked off. The first webinar is taking place today, Monday 21 October 2024 at 12:00 noon CET, with CST experts presenting on “Unlocking the value of CST: A best kept secret”. Brain+ also informs that its initial targeted commercial outreach has led to high-level engagements with the first NHS Trusts and to dialogue with other commissioned providers of CST in the UK. In parallel, results from a detailed customer analysis and segmentation are underway to further inform the company’s commercial activities and feed into a White Paper on the value offerings of Ayla – your CST Assistant, which will be published end October.
Brain+ has taken a multi-faceted approach to entering the dementia care market in the United Kingdom (UK), combining direct engagement with National Health Service (NHS) Trusts, collaboration with third sector providers, educational initiatives, and market research to continuously grow its market understanding and inform its commercial operations. The aim is to firmly position Brain+ and its first launched product, Ayla – your CST Assistant, as a leading solution for scalable dementia care in the UK.
Now, only three (3) weeks after UK launch of Ayla – your CST Assistant, Brain+ informs of initial progress for its commercial activities.
First UK customer engagements
NHS organizations, and more specifically NHS mental health trusts and memory service providing trusts, who offer Cognitive Stimulation Therapy (CST) represent the primary targeted customer segment for Brain+. First outreach by the company’s UK commercial team to present Ayla – your CST Assistant has so far led to high-level commercial discussions with two specific NHS Trusts; one in the North of England and one in the East of England.
These engagements represent important first steps in Brain+' strategy to introduce Ayla - your CST Assistant to key decision-makers within the NHS and generally build its commercial network with NHS partners.
Devika Wood, Chief Commercial Officer of Brain+, commented:
“Our strategic approach to UK market entry is already showing good results and we are being met with solid interest for our Ayla – your CST Assistant solution. We are mindful of the current NHS landscape and are timing our sales and marketing efforts accordingly, including consideration of the upcoming UK budget announcement on 30 October.”
Recognising the importance of diverse partnerships, Brain+ is also targeting engagement with third sector providers, including private healthcare stakeholders and charity organizations, who are already commissioned to deliver CST services to people with dementia. This strategy expands the potential customer base beyond NHS Trusts.
Launch of educational CST webinar series
To further build awareness around its Ayla dementia care platform and engage with NHS Trusts and other stakeholders, Brain+ is launching a series of educational commercial and clinical webinars. The first in this series is titled "Unlocking the value of CST – a best kept secret" and will take place today, Monday, 21 October 2024 (see invitation below). This webinar aims to:
- Introduce the concept of Cognitive Stimulation Therapy (CST)
- Highlight the benefits of CST for people affected by dementia
- Showcase Brain+’ Ayla – your CST Assistant as an innovative solution for delivering digital CST.
Ongoing market intelligence activities
Post-launch market intelligence activities are ongoing for Brain+ to continue to deepen its understanding of the UK healthcare landscape and of specific dementia care and CST delivery processes. This will add to refine the Company’s commercial approach and the presentation of product value offerings accordingly. Responses from these activities are expected to be available in the coming weeks and will feed into a commercial white paper, which will be issued end October to present Ayla – your CST assistant and the benefits of the product to help scale effective delivery of CST.
The Company will provide further updates on its UK commercialisation efforts as significant developments occur.
Invitation to clinical and commercial webinar: “Unlocking the value of CST: A best kept secret”
In line with Brain+’ previously released commercial roll-out plan and awareness campaign for Ayla – your CST Assistant in the UK, Brain+ is hosting a clinical webinar today, 21 October 2024, at 12:00 noon CET under the title “Unlocking the value of Cognitive Stimulation Therapy (CST): A best kept secret”. In the webinar, leading dementia and CST experts will speak on the background and evidenced benefits of CST for people affected by dementia, and the offerings of Ayla – your CST Assistant as the only available solution to offer digital CST will be presented. For more information and to sign up for the webinar: LinkedIn: Invitation to Brain+ webinar on CST and Ayla – your CST Assistant
Contact Information
CEO and Co-founder, Kim Baden-Kristensen: + 45 31 39 33 17 (SMS), [email protected]
CCO, Devika Wood: + +44 742 928 03 66, [email protected]
Brain+ vision:
Building the world’s first scalable dementia care platform to help people affected by dementia, live better lives